While several studies have shown improved responses to immune checkpoint inhibitors in tumors with high mutational burden42,43, a recent pan-cancer study revealed no significant association between mutational burden and CD8 + T-cell infiltration; however, tumor histo-type specific associations do exist44. This evidence concerns the gene CD8A and cancer.